AcroBiosystems leans on overseas sales in renewed Hong Kong listing bid
The company leads the field for recombinant proteins among its domestic peers, but overseas companies dominate the international market Key Takeaways: AcroBiosystems has applied to list in Hong Kong, reporting…
Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
The Chinese firm has lost its regulatory approval to sell a lung cancer drug in Europe over a data-protection error, and must reset the clock on the launch process Key…
Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’
Just 14 months after its market debut, the drug developer is under investigation over regulatory concerns that its IPO demand was artificially inflated Key Takeaways: Cloudbreak’s IPO drew strong retail…
Salubris refiles for Hong Kong IPO as generics lose steam
The producer of cardiovascular drugs is accelerating its shift towards innovative pharmaceuticals, under pressure from price cuts and expiring patents Key Takeaways: Salubris built its early success on generics, but…
Bulging order book for bioconjugates lifts WuXi XDC profits
The provider of outsourced pharmaceutical services has delivered unexpectedly strong half-year earnings and has launched its first overseas production hub Key Takeaways: WuXi XDC began operations in August at a…
Cancer drug sales power up Kelun-Biotech’s profit engine
The firm made more money from precision oncology treatments than from licensing deals in the first half, after gaining insurance coverage for its core drugs in China Key Takeaways: The…
Recent Articles
RELATED ARTICLES
-
Looking for overseas growth, Aier Eye seeks Hong Kong listing
300015.SHE -
Newborn Town leans on better monetization as user growth slows
9911.HK
- ESWIN Computing powers up its RISC-V growth story for Hong Kong investors
- Unsated by Hong Kong listing, Knowledge Atlas seeks more funds in Shanghai
-
Shantui Construction bulldozes its way towards Hong Kong listing
000680.SHE
- Fosun tries again with new Club Med Hong Kong IPO bid
- Avatr parks its NEV listing in Hong Kong, complete with losses and state ownership
